Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?
暂无分享,去创建一个
[1] F. Mazzocchi. Complexity in biology , 2008, EMBO reports.
[2] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[3] Angelo D. Favia,et al. Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.
[4] M. Emerit,et al. Subunit-specific coupling between gamma-aminobutyric acid type A and P2X2 receptor channels. , 2004, The Journal of biological chemistry.
[5] F. Holsboer,et al. Antidepressants and Antipsychotic Drugs Colocalize with 5-HT3 Receptors in Raft-Like Domains , 2005, The Journal of Neuroscience.
[6] J. Sonner,et al. The Anesthetic-Like Effects of Diverse Compounds on Wild-Type and Mutant γ-Aminobutyric Acid Type A and Glycine Receptors , 2008, Anesthesia and analgesia.
[7] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[8] Bruce Tidor,et al. Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment. , 2007, The journal of physical chemistry. B.
[9] S. L. Wong,et al. A Map of the Interactome Network of the Metazoan C. elegans , 2004, Science.
[10] M. Bianchi,et al. Neurosteroids Shift Partial Agonist Activation of GABAA Receptor Channels from Low- to High-Efficacy Gating Patterns , 2003, The Journal of Neuroscience.
[11] M. Bianchi. Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy. , 2008, Medical hypotheses.
[12] M. Bianchi. Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications. , 2010, Medical hypotheses.
[13] Karl Deisseroth,et al. Integration of light-controlled neuronal firing and fast circuit imaging , 2007, Current Opinion in Neurobiology.
[14] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[15] M. Ticku,et al. An update on GABAA receptors , 1999, Brain Research Reviews.
[16] G. Rammes,et al. Modulation of Ligand-gated Ion Channels by Antidepressants and Antipsychotics , 2007, Molecular Neurobiology.
[17] S. Friend,et al. Embracing Complexity, Inching Closer to Reality , 2005, Science's STKE.
[18] Simon K. Mencher,et al. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.
[19] R. Eckenhoff. Promiscuous ligands and attractive cavities: how do the inhaled anesthetics work? , 2001, Molecular interventions.
[20] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[21] S. L. Wong,et al. Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.
[22] D. Weaver,et al. The “promiscuous drug concept” with applications to Alzheimer's disease , 2005, FEBS letters.
[23] Emmanuel J. Botzolakis,et al. Microscopic kinetic determinants of macroscopic currents: insights from coupling and uncoupling of GABAA receptor desensitization and deactivation , 2007, The Journal of physiology.
[24] M. Bianchi,et al. Pentobarbital Differentially Modulates α1β3δ and α1β3γ2L GABAA Receptor Currents , 2004, Molecular Pharmacology.
[25] Ken Solt,et al. Correlating the clinical actions and molecular mechanisms of general anesthetics , 2007, Current opinion in anaesthesiology.
[26] Randall T Peterson,et al. Chemical biology and the limits of reductionism. , 2008, Nature chemical biology.
[27] Sydney S Cash,et al. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. , 2009, Medical hypotheses.
[28] D. Colquhoun,et al. Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.
[29] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[30] J. Fisher,et al. Fluoxetine Increases GABAA Receptor Activity through a Novel Modulatory Site , 2003, Journal of Pharmacology and Experimental Therapeutics.
[31] Eric J. Deeds,et al. Robust protein–protein interactions in crowded cellular environments , 2007, Proceedings of the National Academy of Sciences.
[32] A. Barabasi,et al. High-Quality Binary Protein Interaction Map of the Yeast Interactome Network , 2008, Science.
[33] R. Erickson. From "magic bullet" to "specially engineered shotgun loads": the new genetics and the need for individualized pharmacotherapy. , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[34] Yu Tian Wang,et al. Direct protein–protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors , 2000, Nature.
[35] K. Wohlfarth,et al. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[36] D. Raju,et al. Hetero-oligomerization between GABAA and GABAB Receptors Regulates GABAB Receptor Trafficking* , 2004, Journal of Biological Chemistry.
[37] M. Emerit,et al. Subunit-specific Coupling between γ-Aminobutyric Acid Type A and P2X2 Receptor Channels* , 2004, Journal of Biological Chemistry.
[38] C. Barajas-López,et al. Cross‐talking between 5‐HT3 and GABAA receptors in cultured myenteric neurons , 2007, Synapse.
[39] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.